Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a new biopsy needle unlock personalized pancreatic cancer therapy?

NCT ID NCT05249075

Diagnosis Sponsor: Radboud University Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 21, 2026 · Last updated Aug 21, 2026

Summary

This trial evaluates a new biopsy needle (Micro-Tech FNB) used during endoscopic ultrasound to collect tissue samples from suspected pancreatic tumors. The goal is to see if this needle provides accurate diagnoses and yields enough high-quality tissue for genetic sequencing, which could guide personalized chemotherapy. Adults with suspected pancreatic adenocarcinoma who need a biopsy are eligible to participate.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Micro-Tech FNB needle (a fine needle biopsy device used during endoscopic ultrasound to obtain tissue samples from pancreatic tumors)
What this could lead to
If successful, this needle could improve the accuracy of pancreatic cancer diagnosis and provide better tissue samples for genetic testing, potentially enabling more personalized chemotherapy.
What could go wrong
This is a relatively early study, and the new needle may not prove superior to existing ones. There are also standard risks associated with endoscopic ultrasound procedures, such as bleeding or infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

138 people

The number who actually took part.

Started

Mar 2022

Finished

Jul 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Each patient with clinical suspicion of pancreatic cancer, based on imaging, will be discussed in the multidisciplinary team consultation. When an EUS-FNB is indicated, patients are included if they meet all the inclusion and none of the exclusion criteria. The population will consist of elderly patients, as pancreatic cancer is rarely diagnosed before the age of 55.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18 years and older * Clinical suspicion of pancreatic adenocarcinoma * Indication for obtaining EUS-guided histology of a suspected pancreatic lesion * Written informed consent Exclusion Criteria: * Contra-indications to undergoing an EUS (e.g., oropharyngeal abnormalities) * Altered anatomy (e.g., after previous Whipple-operation, Roux-and-Y gastrojejunostomy) * Contra-indications to the administration of benzodiazepines, propophol or opioids * Pregnancy * Insufficient knowledge of the Dutch language to be able to understand the patient information

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pancreatic adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pancreatic cancer

Contacts and locations

Locations

  • Radboudumc

    Nijmegen, Gelderland, 6525 GA, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.